Secondary Logo

Journal Logo

You can read the full text of this article if you:

Ovid Member Institutional Access
Review Article

Hormone Replacement Therapy: Real Concerns and False Alarms

Bluming, Avrum Z. MD; Tavris, Carol PhD

Author Information
doi: 10.1097/PPO.0b013e31819e332a



In the March/April issue, the review by Dr Avrum Bluming and Carol Tavris entitled, “Hormone Replacement Therapy: Real Concerns and False Alarms,” requires that an additional sentence be added to the disclosure statement.

The new disclosure sentence is: Dr. Bluming wishes to disclose that he has received compensation in the past as an expert witness on behalf of Wyeth Pharmaceuticals (the maker of HT drugs Premarin and Prempro) to consult and advise on litigation.

In addition to the above change, please note there were also changes made to the References column of , which appears on page 94 of the article.

5+ images

Also, on page 96, Table 2, the reference cited for the first 2003 entry should be 34, not 37.

The Cancer Journal. 15(3):262, May-June 2009.

© 2009 Lippincott Williams & Wilkins, Inc.